IGF1 and amyotrophic lateral sclerosis: Nevertheless, recent studies that evaluated systemic administration of scAAV9 encoding Igf-1, and intrathecal injection of IGF-1, observed a slowing of disease progression in mouse ALS models, raising the possibility that a different delivery method could be explored further (Hu et al., 2018; Wang et al., 2018).